AETHLON MEDICAL INC (AEMD)
US00808Y4061 - Common Stock
We assign a fundamental rating of 2 out of 10 to AEMD. AEMD was compared to 187 industry peers in the Health Care Equipment & Supplies industry. The financial health of AEMD is average, but there are quite some concerns on its profitability. AEMD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
AEMD had negative earnings in the past year.
AEMD had a negative operating cash flow in the past year.
AEMD had negative earnings in each of the past 5 years.
AEMD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AEMD has a worse Return On Assets (-147.97%) than 88.77% of its industry peers.
AEMD has a worse Return On Equity (-211.60%) than 78.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -147.97% | ||
| ROE | -211.6% | ||
| ROIC | N/A |
ROA(3y)-90.16%
ROA(5y)-81.14%
ROE(3y)-117.5%
ROE(5y)-100.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for AEMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AEMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AEMD has more shares outstanding
The number of shares outstanding for AEMD has been increased compared to 5 years ago.
AEMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
AEMD has an Altman-Z score of -29.20. This is a bad value and indicates that AEMD is not financially healthy and even has some risk of bankruptcy.
AEMD's Altman-Z score of -29.20 is on the low side compared to the rest of the industry. AEMD is outperformed by 89.30% of its industry peers.
There is no outstanding debt for AEMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -29.2 |
ROIC/WACCN/A
WACC9.14%
2.3 Liquidity
A Current Ratio of 3.40 indicates that AEMD has no problem at all paying its short term obligations.
The Current ratio of AEMD (3.40) is better than 60.43% of its industry peers.
AEMD has a Quick Ratio of 3.40. This indicates that AEMD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AEMD (3.40) is better than 70.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.4 | ||
| Quick Ratio | 3.4 |
3. Growth
3.1 Past
AEMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.49%, which is quite impressive.
The Revenue for AEMD has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)41.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.61%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, AEMD will show a very strong growth in Earnings Per Share. The EPS will grow by 36.48% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y78.77%
EPS Next 2Y36.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AEMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AEMD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AEMD's earnings are expected to grow with 36.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.48%
EPS Next 3YN/A
5. Dividend
5.1 Amount
AEMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AETHLON MEDICAL INC
NASDAQ:AEMD (12/19/2024, 8:16:12 PM)
Premarket: 0.401 -0.03 (-7.48%)0.4334
-0.23 (-34.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners2.99%
Inst Owner Change129.85%
Ins Owners4.64%
Ins Owner Change-2.84%
Market Cap6.05M
Analysts80
Price Target3.93 (806.78%)
Short Float %1.46%
Short Ratio0.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.13%
Min EPS beat(2)-9.2%
Max EPS beat(2)27.47%
EPS beat(4)2
Avg EPS beat(4)6.81%
Min EPS beat(4)-9.2%
Max EPS beat(4)27.47%
EPS beat(8)5
Avg EPS beat(8)4.75%
EPS beat(12)6
Avg EPS beat(12)-5.86%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.05 | ||
| P/tB | 1.05 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.82
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -147.97% | ||
| ROE | -211.6% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-90.16%
ROA(5y)-81.14%
ROE(3y)-117.5%
ROE(5y)-100.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 69.87% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.4 | ||
| Quick Ratio | 3.4 | ||
| Altman-Z | -29.2 |
F-Score2
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)251.07%
Cap/Depr(5y)280.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.61%
EPS Next Y78.77%
EPS Next 2Y36.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.62%
OCF growth 3YN/A
OCF growth 5YN/A